<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057978</url>
  </required_header>
  <id_info>
    <org_study_id>CREDIT-II-131105</org_study_id>
    <nct_id>NCT02057978</nct_id>
  </id_info>
  <brief_title>EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.</brief_title>
  <acronym>CREDIT-II</acronym>
  <official_title>A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Medical Systems Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Medical Systems Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Randomized Study to evaluate the safety and efficacy of the Excel-II DES&#xD;
      compared to the EXCEL DES in the treatment of patients with de novo coronary artery lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary end point is to observe in-stent late lumenn loss after 9 months of the stent&#xD;
      implantation.&#xD;
&#xD;
      This study is based on non-inferior assumption (vs. EXCEL-II V EXCEL Stent), requring all of&#xD;
      end points reach statictic significance.&#xD;
&#xD;
      Quality assurance plan that addresses data validation and registry procedures, including any&#xD;
      plans for site monitoring and auditing.&#xD;
&#xD;
      Data checks to compare data entered into the registry against predefined rules for range or&#xD;
      consistency with other data fields in the registry.&#xD;
&#xD;
      Source data verification to assess the accuracy, completeness, or representativeness of&#xD;
      registry data by comparing the data to external data sources (e.g., medical records, paper or&#xD;
      electronic case report forms, or interactive voice response systems).&#xD;
&#xD;
      Data dictionary that contains detailed descriptions of each variable used by the registry,&#xD;
      including the source of the variable, coding information if used and normal ranges if&#xD;
      relevant.&#xD;
&#xD;
      Standard Operating Procedures to address registry operations and analysis activities, such as&#xD;
      patient recruitment, data collection, data management, data analysis, reporting for adverse&#xD;
      events, and change management.&#xD;
&#xD;
      Sample size assessment to specify the number of participants or participant years necessary&#xD;
      to demonstrate an effect.&#xD;
&#xD;
      Plan for missing data to address situations where variables are reported as missing,&#xD;
      unavailable, &quot;non-reported,&quot; uninterpretable, or considered missing because of data&#xD;
      inconsistency or out-of-range results Statistical analysis plan describing the analytical&#xD;
      principles and statistical techniques to be employed in order to address the primary and&#xD;
      secondary objectives, as specified in the study protocol or plan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>9 months in-stent late lumen loss</measure>
    <time_frame>9 months</time_frame>
    <description>To observe in-stent late lumen loss after 9 months of stent implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>9-m in-segment diameter restenosis rate</measure>
    <time_frame>9 months</time_frame>
    <description>9-m in stent, proximal stent edge, the distal edge segment defined in the restenosis rate, 9-m after lesions within the segment late lumen loss percentage and the diameter of the restenosis degree</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success rates , lesion success rates , clinical success rates Device, lesion, &amp; clinical success rates Device, lesion, &amp; clinical success rates Target Lesion Failure</measure>
    <time_frame>1m,6m,9m,12m,18m and annually to 5years</time_frame>
    <description>Device oriented composite of cardiac death, MI, or ischemia-driven TLR at 1m, 6m, 12m,18m and annually up to 5 yrs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stent thrombosis</measure>
    <time_frame>1m,6m,9m,12m,18m and annually up to 5 yrs</time_frame>
    <description>Definite and probable stent thrombosis according to ARC defination</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">416</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Disease</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>EXCEL DES</arm_group_label>
    <description>Use EXCEL DES implatationas as control group,Implant DES for CAD cases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXCEL-II DES</arm_group_label>
    <description>EXCEL-II DES implantation as control group,Implant DES for CAD cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EXCEL DES implatation</intervention_name>
    <description>Implant DES for CAD cases</description>
    <arm_group_label>EXCEL DES</arm_group_label>
    <other_name>Implant DES for CAD cases</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EXCEL-II DES implantation</intervention_name>
    <description>Implant DES for CAD cases</description>
    <arm_group_label>EXCEL-II DES</arm_group_label>
    <other_name>Implant EXCEL-II DES for CAD cases</other_name>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Endpoint Classification: Safety/Efficacy Study Enrollment: 416 cases [Anticipated]&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will plan for a total of 416 patients with primary, in situ coronary artery&#xD;
        lesions (all of the patients was selected in different blood vessels, a total of up to two&#xD;
        target disease Variable and each target lesion 1 stents, such as placing stents need more&#xD;
        than one in the operation, require the use of the same brand of stents, mix does not&#xD;
        recommend the same patients Other brand support, unless save extra stents.) Choose lesions&#xD;
        reference diameter of 2.5 mm to 2.5 mm (visual), each lesion length 32 mm or less (visual),&#xD;
        participants must conform to the standard can be selected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        1.18yrs≤Age≤75yrs . 2.stability and unstable angina pectoris (AP), chronic myocardial&#xD;
        infarction (OMI) or confirmed myocardial ischemia; 3.De novo lesion at native coronary&#xD;
        artery(Up to two target lesions). 4.Lesion length ≤32mm. 5.RVD 2.5mm～4.0mm. 6.DS%≥70% by&#xD;
        visual test. 7.Coronary artery bypass surgery (coronary artery bypass grafting) patients.&#xD;
        8.Subjects are willing to follow the specified requirements follow-up. 9.To understand the&#xD;
        purpose of the trial and willing to sign informed consent and accept clinical follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AMI within 7 days.&#xD;
&#xD;
          2. CTO (TIMI 0), the left main lesion, ostial lesion and transplant vascular lesions, the&#xD;
             bifurcation lesion (reference collateral blood vessel diameter of 2.5 mm or higher),&#xD;
             stent restenosis lesions and to deal with three pathological changes;&#xD;
&#xD;
          3. Severe calcified lesion unable to predilate.&#xD;
&#xD;
          4. The distortion of the stent was hampered by lesions.&#xD;
&#xD;
          5. NYHA≥Ⅲ or LVEF&lt;40%.&#xD;
&#xD;
          6. Prior PCI within 1 year.&#xD;
&#xD;
          7. Pregnancy or lactation, and planning pregnancy or lactation.&#xD;
&#xD;
          8. Subjects have bleeding tendency or blood coagulation dysfunction or PCI&#xD;
             contraindications, or anticoagulant therapy taboo or can't continue to take DAPT at&#xD;
             least 1 year.&#xD;
&#xD;
          9. There are other diseases (such as cancer,malignant tumor ,congestive heart&#xD;
             failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin,&#xD;
             etc.), scheme compliance is poor, interference related data explanation or the limited&#xD;
             life (&lt; 1 year).&#xD;
&#xD;
         10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast&#xD;
             agent of one of allergy.&#xD;
&#xD;
         11. Serious liver and kidney function are not complete subject(ALT and AST were three&#xD;
             times greater than the upper limit of normal).&#xD;
&#xD;
         12. Before enrolling to participate in other clinical trials and not reached the primary&#xD;
             endpoint.&#xD;
&#xD;
         13. Non-compliant subject and could not finish the trial in accordance with the&#xD;
             requirements of the subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Yaling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenyang Northern Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shenyang Northern Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2014</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Late Lumen Loss</keyword>
  <keyword>MACE</keyword>
  <keyword>Death</keyword>
  <keyword>TLF</keyword>
  <keyword>Thrombosis(definite or probable )</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

